Schizophrenia Drugs Market to Reach $17.4 Billion by 2035

Schizophrenia drugs market was valued at $10.2 billion in 2025 and is projected to reach $17.4 billion by 2035, growing at a CAGR of 5.6%. A key macro driver is the rising global burden of mental disorders, as highlighted by the OECD, which reports significantly higher mortality rates among individuals with schizophrenia compared to the general population. This underscores the urgent need for effective long-term treatment solutions and improved access to care. Additionally, a 2025 study published on PubMed Central indicates that current treatment options primarily focus on symptom management rather than cure, due to the complex and not fully understood nature of the disorder. Existing antipsychotic therapies mainly address positive symptoms such as hallucinations and delusions but are often associated with long-term side effects. This has led to growing research interest in novel therapeutic approaches beyond traditional dopamine-based mechanisms. Together, these factors are driving innovation and sustained demand in the global schizophrenia drugs market.

Browse the full report description of “Schizophrenia Drugs Market Size, Share & Trends Analysis Report by Drug Class (Second Generation Antipsychotics, Third Generation/ Novel Mechanism Drugs), by Route of Administration (Oral, Injectable, Transdermal), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/schizophrenia-drugs-market

Innovation Leaders Transforming the Schizophrenia Drugs Market

The key players in the schizophrenia drugs market include Johnson & Johnson, Pfizer, AbbVie, Bristol Myers Squibb, and AstraZeneca, among others. These companies are accelerating innovation through next-generation antipsychotics, long-acting injectable (LAI) therapies, and novel drug mechanisms. Their strategies focus on improving patient adherence, minimizing relapse risks, and enhancing long-term treatment outcomes. Growing investments in CNS pipelines and strategic collaborations are further strengthening global drug development and commercialization efforts.

• In March 2026, Bristol Myers Squibb reported that its open-label study showed symptom stability in patients switching from oral atypical antipsychotics to Cobenfy (xanomeline and trospium chloride). The findings highlight the drug’s potential as a novel treatment option with a different mechanism of action, supporting ongoing innovation in schizophrenia therapy.

• In September 2025, Johnson & Johnson announced it would showcase its neuropsychiatry portfolio and pipeline innovations at the Psych Congress Annual Meeting, including advancements in schizophrenia treatments. The update highlights the company’s continued focus on next-generation therapies and long-acting formulations, supporting ongoing innovation in the CNS drug landscape.

• In November 2024, AbbVie reported Phase 2 results for emraclidine, a novel schizophrenia drug, which failed to meet its primary endpoints in clinical trials, showing no significant improvement over placebo. Despite demonstrating a favorable safety profile, the outcome highlights the challenges and uncertainties in developing next-generation antipsychotics. The setback underscores the competitive landscape and reinforces the need for continued innovation in novel mechanisms beyond traditional therapies.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-

• By Drug Class
• By Treatment
• By Route of Administration
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape Johnson & Johnson, Pfizer, AbbVie, Bristol Myers Squibb, and AstraZeneca, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Schizophrenia Drugs Market Report Segment

By Drug Class

• First Generation Antipsychotics
• Second Generation Antipsychotics
• Third Generation / Novel Mechanism Drug

By Route of Administration

• Oral
• Injectable

Global Schizophrenia Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/schizophrenia-drugs-market